Peptides

A 15-amino acid fragment derived from a protective peptide originally identified in human gastric juice. Studied extensively in animal models — particularly rodent research — for its effects on tissue repair pathways including tendon, ligament, muscle, and gut tissue. Early-stage interest in its interaction with growth factor signaling and angiogenesis. First synthesized and described in scientific literature in the early 1990s. Not approved by the FDA for human use; sold for research purposes only.

A higher-strength 10 mg vial of the same BPC-157 compound described in the standard entry in this catalog — see that entry for full background on its research history and studied mechanisms. Supplied for researchers seeking a larger total peptide quantity per vial for higher-volume laboratory applications. Studied in the same body of animal-model literature investigating tendon, ligament, muscle, and gut tissue repair pathways, along with growth factor signaling and angiogenesis. Not approved by the FDA for human use; sold for research purposes only.

A synthetic fragment derived from thymosin beta-4, a naturally occurring polypeptide found in nearly every cell type. Studied in research literature for its role in actin binding and cell migration, with research interest in tissue repair, recovery, and inflammation pathways in animal models. Closely related compounds have been investigated in early cardiovascular and tissue-repair clinical trials. Not approved by the FDA for human use; sold for research purposes only.

A naturally occurring tripeptide that binds copper ions, found in human plasma at high concentrations in newborns and declining with age. One of the most extensively studied peptides in dermatology research — investigated for its role in collagen synthesis, copper transport, and wound-repair pathways. Frequently referenced as a comparison compound in skincare and tissue-repair literature. Not approved by the FDA for human therapeutic use; sold for research purposes only.

A tripeptide fragment derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone (ACTH). Studied in research literature for its anti-inflammatory properties independent of pigmentation-related melanocortin activity, with particular research interest in gut inflammation, dermal inflammation, and skin-barrier research models. Investigated in animal studies for its interaction with inflammatory signaling pathways such as NF-κB, without the receptor-binding profile associated with pigmentation-focused melanocortin analogs. Frequently referenced alongside other tissue-repair peptides in combination-research contexts. Not approved by the FDA for human use; sold for research purposes only.

A pentapeptide that interacts with the ghrelin receptor as a growth hormone secretagogue. First described in scientific literature in the late 1990s as a more selective compound than earlier secretagogues. Studied in animal models for its effects on the growth hormone axis and for its receptor selectivity profile. Not approved by the FDA for human use; sold for research purposes only.

A synthetic analog of growth hormone-releasing hormone (GHRH). The 'No DAC' designation distinguishes this version from analogs that include a Drug Affinity Complex modification — the No DAC variant has a shorter half-life. Studied in research models for its effects on GHRH receptor signaling and the pulsatile pattern of growth hormone secretion. Not approved by the FDA for human use; sold for research purposes only.

A long-acting analog of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) — a chemical modification that promotes binding to circulating albumin and extends the compound's half-life relative to non-DAC GHRH analogs. Distinct from the shorter-acting CJC-1295 (No DAC) variant also referenced in this catalog. Studied in research models for its sustained interaction with the GHRH receptor and its influence on the pulsatile release pattern of growth hormone and downstream IGF-1 signaling. Frequently referenced in growth-hormone-axis literature alongside ghrelin-receptor secretagogues. Not approved by the FDA for human use; sold for research purposes only.

A synthetic analog of growth hormone-releasing hormone (GHRH), originally developed and studied in clinical contexts for its effects on the growth hormone axis and visceral adipose tissue. The material stocked here is a research-grade analog, sold separately from any FDA-approved pharmaceutical product, intended for laboratory and research applications only. Referenced extensively in endocrinology and metabolic literature examining GHRH receptor signaling, IGF-1 response, and visceral fat distribution in study models. Distinguished from other GHRH analogs by an added trans-3-hexenoic acid group studied for its effect on peptide stability. Not for human consumption; not a substitute for prescription medication. Speak with our staff for product information.

A combination product pairing CJC-1295, a synthetic GHRH analog, with Ipamorelin, a ghrelin-receptor-selective growth hormone secretagogue — see each compound's individual catalog entry for its respective mechanism. The two are commonly referenced together in research literature exploring synergistic stimulation of the growth hormone axis, with GHRH and ghrelin-receptor pathways studied as complementary rather than redundant signaling routes. Supplied as a 5 mg / 5 mg combined-vial product. Studied in animal and in-vitro models for pulsatile GH release patterns and receptor cross-talk. Not approved by the FDA for human use; sold for research purposes only.

A combination product pairing BPC-157, a gastric-derived pentadecapeptide fragment, with TB-500, a synthetic fragment of thymosin beta-4 — nicknamed "Wolverine" in research-community shorthand for the pairing's association with combined tissue-repair research interest. See each compound's individual catalog entry for its respective mechanism and research history. The two peptides are frequently studied together in animal models investigating overlapping but distinct pathways: BPC-157's interaction with growth factor signaling and angiogenesis, and TB-500's role in actin binding and cell migration. Supplied as a 10 mg / 10 mg combined-vial product. Not approved by the FDA for human use; sold for research purposes only.

A lower-strength 5 mg / 5 mg version of the combined BPC-157 / TB-500 "Wolverine" blend also listed in this catalog — see that entry for a full description of each compound's individual mechanism and the pairing's research background. Supplied as a smaller combined vial for researchers seeking a reduced total peptide quantity. Studied in the same body of animal-model literature examining overlapping tissue-repair, growth-factor-signaling, and cell-migration pathways associated with the two compounds. Not approved by the FDA for human use; sold for research purposes only.

A research-community blend combining GHK-Cu, BPC-157, and TB-500 — three peptides each referenced individually elsewhere in this catalog. GHK-Cu is studied extensively in dermatology research for collagen synthesis and copper transport, while BPC-157 and TB-500 are studied in animal models for tissue-repair, growth-factor-signaling, and cell-migration pathways. Informal research and skin-focused literature has associated the combined formula with overlapping interest in dermal and tissue-repair research, though the blend itself has not been independently studied to the extent of its individual components. Supplied as a 70 mg combined-vial product. Not approved by the FDA for human use; sold for research purposes only.

A research-community blend built on the GLOW formula — GHK-Cu, BPC-157, and TB-500 — with KPV added, a tripeptide fragment of ACTH referenced individually elsewhere in this catalog for its anti-inflammatory research profile. Informal research and skin-focused literature has associated the combined formula with overlapping interest in tissue-repair and anti-inflammatory research, extending GLOW's dermal-research association with KPV's studied interaction with inflammatory signaling pathways. As with GLOW, the combined formula itself has not been independently studied to the same extent as its individual components. Supplied as an 80 mg combined-vial product. Not approved by the FDA for human use; sold for research purposes only.

A GLP-1 receptor agonist originally developed and approved as a prescription medication for specific clinical indications. The research-grade analog stocked here is sold separately from any FDA-approved pharmaceutical product, intended for laboratory and research applications only. Used in research investigating incretin signaling pathways. Not for human consumption; not a substitute for prescription medication. Speak with our staff for product information.

A dual GIP and GLP-1 receptor agonist originally developed and approved as a prescription medication. The research-grade analog stocked here is sold separately from any FDA-approved pharmaceutical product, intended for laboratory and research applications only. Used in research investigating the dual incretin pathway — a major focus area in metabolic research. Not for human consumption; not a substitute for prescription medication. Speak with our staff for product information.

A research-grade peptide analog studied for its interaction with multiple incretin-pathway receptors, building on the broader body of GLP-1 and dual-agonist literature referenced elsewhere in this catalog. Positioned in research contexts as an investigational multi-receptor incretin agonist, used in laboratory settings to study combined receptor engagement and downstream metabolic signaling. This is not an FDA-approved pharmaceutical product under any name and is not manufactured or marketed as a substitute for one. Supplied as a 10 mg vial for research applications only. Not for human consumption; not a substitute for prescription medication. Speak with our staff for product information.

A higher-strength 30 mg vial of the same multi-receptor incretin pathway research analog described in the 10 mg GLP-3RT entry in this catalog — see that entry for full background on its research context and mechanism. Intended strictly for laboratory and research use in studies of multi-receptor incretin signaling. This is not an FDA-approved pharmaceutical product and is not manufactured or marketed as a substitute for one. Not for human consumption; not a substitute for prescription medication. Speak with our staff for product information.

A peptide encoded within the mitochondrial genome, identified as one of several "mitochondrial-derived peptides" discovered through genomic research in the 2010s. Studied in animal models for its role in regulating cellular energy metabolism, including AMPK pathway activation and glucose homeostasis under metabolic stress. Referenced extensively in aging and exercise-physiology research literature examining the relationship between mitochondrial signaling and whole-body metabolic function. Continues to be an active subject of laboratory research into cellular bioenergetics and longevity-adjacent pathways. Not approved by the FDA for human use; sold for research purposes only.

A synthetic tetrapeptide designed to selectively concentrate in the inner mitochondrial membrane, where it associates with cardiolipin. Studied extensively in laboratory research for its role in mitochondrial bioenergetics, including effects on electron transport chain efficiency and reduction of reactive oxygen species in cellular models. Investigated in clinical research settings under the name elamipretide for select cardiac and mitochondrial-disease indications, though the material stocked here is a research-grade compound sold separately from any pharmaceutical product. Referenced widely in cellular-aging and bioenergetics literature. Not approved by the FDA for human use as sold here; sold for research purposes only.

Nicotinamide adenine dinucleotide (NAD+) is a naturally occurring coenzyme central to cellular energy metabolism and redox reactions — technically a dinucleotide rather than a peptide, though commonly stocked and studied alongside peptide research compounds. Extensively referenced in aging and cellular-metabolism research literature examining declining NAD+ levels with age and their relationship to mitochondrial function, sirtuin activity, and DNA repair pathways. Supplied as a 100 mg vial for laboratory and research use. Research in this area remains at early stages regarding translation to human outcomes. Not approved by the FDA for human use; sold for research purposes only.

A higher-strength 500 mg vial of the same nicotinamide adenine dinucleotide (NAD+) coenzyme described in the 100 mg entry in this catalog — see that entry for background on its research context. Supplied for researchers seeking a larger total quantity per vial. As with the 100 mg vial, this is a nucleotide-derived molecule rather than a peptide, studied in cellular-metabolism and aging research for its role in redox reactions and mitochondrial function. Not approved by the FDA for human use; sold for research purposes only.

A synthetic peptide analog of tuftsin, developed by Russian researchers at the Institute of Molecular Genetics in the 1990s. Studied extensively in Russian-originated research literature for its investigated anxiolytic and nootropic properties in animal models, with research interest in its effects on GABA and serotonin signaling, brain-derived neurotrophic factor (BDNF) expression, and enzymatic breakdown of enkephalins. Referenced in a body of Eastern European clinical and preclinical literature examining stress-response and cognitive-performance pathways, though this research base has not been replicated to the same extent in Western regulatory contexts. Not approved by the FDA for human use; sold for research purposes only.

A synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH), developed by Russian researchers and studied since the 1980s. Referenced extensively in Russian-originated preclinical and clinical literature for its investigated neuroprotective and nootropic properties, including research interest in BDNF expression, cerebral blood flow, and cognitive-performance measures in animal models. Structurally modified from the native ACTH fragment to resist rapid enzymatic degradation. As with other compounds originating primarily from Eastern European research literature, findings have not been independently replicated to the same extent in Western regulatory frameworks. Not approved by the FDA for human use; sold for research purposes only.

A synthetic nonapeptide first isolated from the cerebral venous blood of rabbits during delta-wave sleep research in the 1970s. Studied in animal and early human research literature for its association with delta-wave (slow-wave) sleep patterns and circadian sleep-regulation pathways. Research interest has also extended to its potential relationship with stress-hormone regulation and pain-signaling pathways, though the precise mechanism of action remains an active subject of laboratory investigation. Referenced across several decades of sleep-research literature as a comparison compound for studying sleep architecture. Not approved by the FDA for human use; sold for research purposes only.

A synthetic analog of α-melanocyte-stimulating hormone (α-MSH). Studied in research literature for its interaction with melanocortin receptors — particularly MC1R and MC4R. Research interest in pigmentation biology and melanocortin signaling. Not approved by the FDA for human use; sold for research purposes only.

A synthetic peptide analog derived from the melanocortin family, structurally related to Melanotan II and studied for its interaction with melanocortin receptors — particularly MC4R, distinct from the MC1R-focused pigmentation research associated with other analogs in this class. Investigated in research literature examining melanocortin-receptor involvement in sexual-arousal-pathway signaling, with related compounds studied in clinical research under the name bremelanotide. The material stocked here is a research-grade compound sold separately from any FDA-approved pharmaceutical product. Referenced frequently alongside Melanotan II in comparative melanocortin-receptor research. Not approved by the FDA for human use as sold here; sold for research purposes only.

A synthetic, stable form of vitamin B-12, an essential water-soluble nutrient involved in red blood cell formation, neurological function, and DNA synthesis. Cyanocobalamin is one of the most widely studied and commercially available forms of B-12 in nutrition and wellness research literature, valued for its stability in solution relative to other cobalamin forms. Frequently referenced in research examining B-12 status, absorption, and its relationship to energy metabolism and neurological health in populations at risk of deficiency. This listing describes a research/wellness-grade material and is not a substitute for guidance from a licensed physician regarding personal nutrient status. Not approved by the FDA as a treatment for any condition; sold for informational and research purposes only.

A glycoprotein hormone naturally produced during pregnancy, referenced in endocrinology research literature for its structural similarity to luteinizing hormone and its interaction with the same receptor. Studied in research examining the hypothalamic-pituitary-gonadal axis and gonadal hormone signaling. HCG is also a regulated prescription drug with FDA-approved clinical uses; those uses require a licensed prescriber and are entirely separate from this listing. The material described here is a separately sourced research-grade product, supplied as a 5,000 IU vial for laboratory and research applications only — it is not dispensed as, represented to be, or a substitute for an FDA-approved pharmaceutical, and it is not for human consumption. Speak with our staff for product information.

A naturally occurring tripeptide composed of glutamine, cysteine, and glycine, produced endogenously in nearly all human cells and recognized as one of the body's primary intracellular antioxidants. Widely referenced in wellness and cellular-research literature examining oxidative stress, detoxification-pathway support, and cellular health. Studied for its role in neutralizing free radicals and regenerating other antioxidants such as vitamins C and E. Supplied as a 1,500 mg vial for research and wellness applications. This listing describes a research/wellness-grade material and does not constitute a claim to treat, cure, or prevent any disease. Not approved by the FDA to treat any condition; consult a licensed physician for personal health guidance.